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ABSTRACT 
Lumefantrine is a widely used antimalarial in children in sub-Saharan Africa and is 
predominantly metabolised by CYP3A4.  The concomitant use of lumefantrine with the 
antiretroviral efavirenz, which is metabolised by CYP2B6 and is an inducer of CYP3A4, 
increases the risk of lumefantrine failure and can result in an increased recrudescence rate in 
HIV-infected children. This is further confounded by CYP2B6 being highly polymorphic 
resulting in a 2-3 fold higher efavirenz plasma concentration in polymorphic subjects, which 
enhances the potential for an efavirenz-lumefantrine drug-drug interaction (DDI).  This study 
developed a population-based PBPK model capable of predicting the impact of efavirenz-
mediated DDIs on lumefantrine pharmacokinetics in African paediatric population groups, 
which also considered the polymorphic nature of CYP2B6. The validated model demonstrated 
a significant difference in lumefantrine target day 7 concentrations (Cd7) in the presence and 
absence of efavirenz and confirmed the capability of efavirenz to initiate this DDI. This was 
more apparent in the *6/*6 compared to *1/*1 population group and resulted in a significantly 
lower (P <0.001) lumefantrine Cd7. A prospective change in dosing schedule from 3-days to 7-
days resulted in a greater number of *6/*6 subjects (28-57%) attaining the target Cd7 across age 
bands (0.25-13 years), with the greatest increase evident in the 1-4 year old group (3-day: 1%; 
7-day: 28%). 
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1. INTRODUCTION 
Malaria represents a considerable healthcare burden, with the World Health Organisation 
(WHO) attributing an estimated 212 million malaria cases and 429 000 malaria-related deaths 
in 2015. Out of those malaria cases and deaths, 92% are from African regions and 
predominantly occur in children aged under 5 years (World Health Organisation, 2016).  
Lumefantrine, often combined with artemether, is one of the most widely used antimalarials in 
sub-Saharan Africa, and many countries adopted it as first line therapy for uncomplicated 
falciparum malaria, including children with HIV co-infection (Flateau et al., 2011). Typical 
treatment regimens for lumefantrine in children include a 3 day six-dose regimen which is 
stratified based on body weight: 5-15 kg 1 tablet per dose; 15-25 kg 2 tablets per dose; 25-35 
kg 3 tablets per dose and >35 kg 4 tablets per dose, with each tablet providing 120 mg 
lumefantrine (World Health Organisation, 2016a). 
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is predominantly 
metabolised by CYP2B6 (Ogburn et al., 2010) and is an inducer of CYP3A4 (Hariparsad et al., 
2004; Shou et al., 2008).  It is a common first-line treatment in paediatrics or pregnancy 
population groups (2013) (Dybul et al., 2002). Lumefantrine is predominantly metabolised by 
CYP3A4 and, although lumefantrine therapy has a wide therapeutic window (Bharti et al., 
2016), patients who are exposed to CYP3A4 inducers, such as efavirenz, may demonstrate 
reduced lumefantrine exposure which can lead to increased recrudescence rates and therapeutic 
failure (Maganda et al., 2016a).  However, this process is further confounded by the fact that 
CYP2B6 is highly polymorphic with at least 37 distinct star-alleles (Zanger and Klein, 2013) 
with *1/*1 carriers considered as wild-type.  The most common variant alleles result in two 
amino acid changes, Q172H and K262R, and is termed CYP2B6*6, and which has been 
reported to lead to a 65 % reduction in protein expression and 50 % reduction in mean enzyme 
activity in the homozygous state (Lang et al., 2001).   
Although CYP2B6 contributes towards between 2-10% of total CYP content (Wang and 
Tompkins, 2008), the impact of the *6/*6 genotype can often result in a 2- or 3-fold higher 
efavirenz plasma concentration (Haas et al., 2004; Rodriguez-Novoa et al., 2005; Rotger et al., 
2005; Tsuchiya et al., 2004).  A consequence of this alteration in efavirenz plasma 
concentration would be a greater ability of efavirenz to induce CYP3A4 (Habtewold et al., 
2013; Hariparsad et al., 2004; Mouly et al., 2002) and thereby enhance the potential for an 
efavirenz-lumefantrine DDI.  
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Importantly, the *6/*6 polymorphism is more frequent in African population groups than 
Caucasian population groups (King and Aberg, 2008; Klein et al., 2005), and this places a 
considerable risk-burden on this geographic population group.  However, the impact of 
CYP2B6 polymorphisms in antiretroviral-antimalarial mediated DDIs in African paediatric 
populations is lacking, and warrants investigation as it may contribute to significantly increased 
the risk of recrudescence especially in highly endemic regions and potential resistance towards 
these antimalarial treatments (Achan et al., 2012; Barnes et al., 2008; Khoo et al., 2005; 
Organization, 2016).  This is further confounded by the risk of placental transfer of HIV (Drake 
et al., 2014) and/or malaria (World Health Organisation, 2016b), and the lack of naturally 
acquired immunity towards children, often puts paediatric population groups at significant risk 
of succumbing to either infection or being exposed to complex DDIs (Doolan et al., 2009). 
Due to the complexity and ethical issues of recruitment of paediatrics into complex DDI studies 
in HIV-infected malaria subjects, population-based physiologically-based pharmacokinetic 
(PBPK) modelling can be used to explore the potential risk of DDIs in adults (Feng and Varma, 
2016; Johansson et al., 2016; Olafuyi et al., 2017a) and paediatric populations (Johnson et al., 
2014; Olafuyi et al., 2017b; Salem et al., 2013a; Salem et al., 2013b).   The benefit of this 
approach is both the ability to model population variability in physiology (Jamei et al., 2009a; 
Jamei et al., 2009b; Jamei et al., 2009c; Olafuyi et al., 2017a, b), but to also specifically develop 
a modelling approach that is tailored towards a specific geographical population group of 
interest rather than a standard healthy (Caucasian) adult male. 
The objectives of the present study were 2-fold: (i) to predict efavirenz pharmacokinetics in 
African population groups (adults and paediatrics) and (ii) to assess the impact of efavirenz in 
the attenuation of lumefantrine pharmacokinetics through a CYP3A4 induction effect.  In all 
cases, it was important also to address the impact of the *6/*6 CYP2B6 phenotype on efavirenz 
pharmacokinetic and the effect of this to alter lumefantrine pharmacokinetics following a DDI. 
2. METHODS 
Population based PBPK modelling was conducted using the virtual clinical trials simulator 
Simcyp (Simcyp Ltd., a Certara company, Sheffield, UK, Version 16).  For all simulations, 
doses for both lumefantrine and efavirenz were employed according to the standard weight-
based dose regimen (See supplementary materials table S1), unless stated otherwise.  Further, 
for all lumefantrine simulations, dosing occurred under fed-conditions unless otherwise 
indicated. 
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2.1 Model development 
A five-stage stepwise approach was implemented for model development, validation and 
model refinement (Figure 1) which is fully described below.  Unless otherwise stated, efavirenz 
was dosed for 20 days prior to initiation of a DDI (and throughout the study). Lumefantrine 
was dosed at over 3 days at 0, 8, 24, 36, 48 and 60 hours. 
2.1.1 Step 1: Adult simulations with efavirenz 
The Simcyp library compound efavirenz was selected, having already been developed and pre-
validated by Simcyp (Ke et al., 2016).  The metabolism of efavirenz was modelled using the 
application of allele-specific intrinsic clearance (CLint) for *1/*1 and *6/*6 genotypes, as 
described by Xu et al (Xu et al., 2013).  Subsequently, when simulating either entirely *1/*1 
(EM) or *6/*6 (PM) genotypes, the frequency of CYP2B6 genotype was set at 1 for either 
*1/*1 or *6/*6.  For efavirenz, unless otherwise stated, doses were administered to steady state 
or beyond (at least 20 days) prior to the initiation of lumefantrine dosing. 
Step 1 attempted to apply the compound file to model predictions in Healthy Volunteer 
(Caucasian), South African and Ugandan population groups, which were generally the focus 
of clinical studies identified. 
Clinical studies selected included: (i) A single 600 mg oral dose to healthy adult volunteers 
with results genotyped for *1/*1 and *6/*6 (Xu et al., 2013) and (ii) a 600 mg once daily multi-
dose study over 32 weeks in Ugandan adults (Mukonzo et al., 2014).   
The Ugandan population group was developed from reported age-weight relationships for 
Ugandan males and females (Hayes et al., 2015), and are detailed in the supplementary 
materials.  A similar approach was reported and applied in PBPK modelling by our group 
(Olafuyi et al., 2017a). In the absence of literature reported abundance of CYP2B6 in Ugandan 
subjects, we fixed *1/*1 and *6/*6 genotype abundances to 6.9 and 2.4 pmol/mg protein, 
respectively, based upon adaptations found in a South African population group developed by 
Simcyp as part of the Critical Path to TB Drug Regimens (CPTR) (Critical Path to TB Drug 
Regimens, 2016) and which is available from population library repository of Simcyp.  The 
South African population group includes appropriate age-weight-height distributions, CYP 
expression and blood biochemistry changes compared to standard (Caucasian) Healthy 
Volunteer population group (Gardner, 2016).  All simulations replicated the study design 
reported by the validation clinical studies cited above. 
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2.1.2 Step 2: Adult simulations with lumefantrine-efavirenz drug-drug interactions 
The validation of the lumefantrine-efavirenz DDI was conducted using two published clinical 
studies: (i) dosing of a single oral dose of 480 mg lumefantrine and 600 mg efavirenz to a 
Healthy Volunteer population group (Huang et al., 2012) where no genotyping was reported 
and (ii) dosing of 480 mg lumefantrine (6 doses, twice daily for 3 days) and 600 mg efavirenz 
(20 days prior to lumefantirne and then throughout the study duration) to a Tanzanian 
population group where genotyping of plasma concentration profiles were reported (Maganda 
et al., 2016b). As a result of similar age-weight relationships (Hayes et al., 2015), the South 
African population group was used as a surrogate for a Tanzanian population. 
2.1.3 Step 3: Paediatric simulations with efavirenz 
After successful validation and refinement of efavirenz compound in the adult population, this 
step focussed on the validation of efavirenz in paediatrics.  
The studies used for validation of efavirenz pharmacokinetics in paediatrics included: (i) 
weight-based once daily 300 mg dose of oral efavirenz in HIV-infected Ugandan children and 
simulated using the Ugandan population group with dosing to steady state (Fillekes et al., 2011) 
(ii) weight-based once daily dose of oral efavirenz in HIV-infected children with weight-based 
stratification of plasma concentration profiles (Luo et al., 2016) simulated using the Ugandan 
population group; (iii) a single high dose (25 mg/kg) dosed once daily to 2-3 year old Ugandan 
children and simulated using the Ugandan population group (Pressiat et al., 2017) and (iv) a 
single oral 300 mg dose administered to 6-7 year old South African subjects and simulated 
using the South African population group (Viljoen et al., 2012) with genotyping of plasma 
concentration profiles. 
2.1.4 Step 4: Paediatric simulations with lumefantrine-efavirenz drug-drug 
interactions  
To validate the prediction of a lumefantrine-efavirenz based DDIs in paediatrics, we utilised 
the only study reporting the lumefantrine plasma concentration-time profile in the absence and 
presence of efavirenz (Parikh et al., 2016), although this study did not report genotyped 
pharmacokinetics.  Trial simulations were performed using a standard 6-dose regimen of 
weight-based dosing of lumefantrine (see supplementary materials table S1) administered on 
day 20 (unless otherwise indicated), with weight-based dosing of efavirenz from day 1 to day 
40 in Ugandan children and simulated using the Uganda population group. To account for the 
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impact of genotype on the pharmacokinetics of lumefantrine, our results were stratified for two 
extreme cases of an entire population of CYP2B6 *1/*1 or entirely CYP2B6 *6/*6, and this 
represents the ‘best’ and ‘worst’ clinical scenarios. 
2.1.5 Step 5: Paediatric dose evaluation prediction 
Having validated the lumefantrine (LUM) and efavirenz (EFV) DDIs in Ugandan paediatric 
patients, this step simulated the potential impact of dosage regimen alterations on target day-7 
(Cd7) lumefantrine plasma concentrations.  Simulations were run using the Ugandan population 
group and stratified across 4 age groups with weight-based dosing (see supplementary 
materials): 0.25-1 year-old (120mg LUM/300mg EFV), 1-4 year-old (120mg LUM/400mg 
EFV), 4-8 year-old (240mg LUM/500mg EFV) and 8-13 year-old (240mg LUM/600mg EFV). 
Further, each simulation included 100 subjects (10 trials with 10 subjects per trial) where the 
age-weight distribution matched the appropriate dose banding.  
2.2 Predictive performance 
In all simulations, a prediction to within 2-fold of the observed data was generally accepted as 
part of the ‘optimal’ predictive performances range despite there being no uniform standard of 
acceptance to determine this criterion (Edginton et al., 2006; Ginsberg et al., 2004; Parrott et 
al., 2011). This acceptance criterion was used in our Cmax and AUC comparisons with the 
published clinical data reported. For the efavirenz DDI simulations, since the therapeutic 
efficacy of lumefantrine is determined by its Cd7 of 280 ng/mL (Ezzet et al., 2000), a direct 
analysis of lumefantrine day-7 concentration was set as a cut-off value to determine the impact 
of a DDI in lumefantrine pharmacokinetics. 
2.3 Data analysis 
The observed data that was used for visual predictive checks when compared with the 
simulated profiles were extracted using the WebPlotDigitizer v.3.10 
(http://arohatgi.info/WebPlotDigitizer/). All simulations of plasma concentration-time profiles 
were presented in 5th to 95th percentiles and either in mean or median unless otherwise 
specified. 
For all adult simulations, age ranges and subject gender ratios were matched, where possible, 
to reported clinical studies.  Where this information was not cited in clinical studies, a default 
age range of 20-50 years and gender ratio of 50% was selected. 
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For simulations employing weight-based dosing, unless otherwise stated, a 100-subject 
simulation was run in a 10x10 trial (10 subjects per trial with 10 trials) to ensure that reasonable 
inter-/intra individual variability is captured within the model simulations.  However, as 
simulations are not possible with defined age and weight ranges, pooling and post-processing 
of output data were conducted to match individuals to the required age-weight boundary 
conditions for the study.  
3. RESULTS  
3.1 Step 1: Adult simulations with efavirenz 
In order to predict the impact of efavirenz-mediated DDIs on lumefantrine pharmacokinetics, 
the capability of the model to predict efavirenz pharmacokinetics alone within a Healthy 
Volunteer population was first assessed.  Using the efavirenz compound file within the Simcyp 
library and the Simcyp ‘Healthy Volunteer’ population group, the predicted population plasma 
concentration time profile for a single 600 mg oral dose of efavirenz were within the range of 
observed reported values for both *1/*1 (Supplementary materials Figure S1A) and *6/*6 
population groups (Supplementary materials Figure S1B) 
Furthermore, the model predicted tmax, Cmax and AUC were within 2-fold of the reported 
parameters for each genotype (Table 1). 
 
Table 1: Summary of predicted and observed pharmacokinetic parameters of efavirenz 
in adults with CYP2B6*1/*1 and CYP2B6*6/*6 genotypes in a Healthy Volunteer 
population 
                        Pharmacokinetic parameters 
  
 Genotype 
 
tmax  
(h) 
Cmax 
(ng/ml) 
AUC0-inf 
(ng/mL.h) 
Observed *1/*1 2.3 ± 1.0 2300 ± 700 79800 ± 28400 
Predicted *1/*1 1.5 ± 0.02 2643 ± 53 59126 ± 1520      
Observed *6/*6 2.7 ± 1.5 2400 ± 200 101700 ± 7900 
Predicted *6/*6 1.5 ± 0.02 2727 ± 136 93857 ± 4693 
Data represents mean ± SD. Simulations: n=20 with 50 % female and age range of 20-50 
years.  
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Subsequently, to further validate model simulations, the ability to predict efavirenz plasma 
concentrations following multi-dosing was assessed in each genotype patient group using a 
Ugandan population group.  In both *1/*1 (Supplementary materials Figure S2A) and *6/*6 
(Supplementary materials Figure S2B) populations, the predicted concentrations were all 
within 2-fold of reported concentrations (Mukonzo et al., 2014) (Table 2) (Supplementary 
materials Figure S2B) 
Table 2: Summary of predicted and observed efavirenz plasma concentrations in 
Ugandan adults with CYP2B6*1/*1 and CYP2B6*6/*6 genotypes. 
Sampling day 
  *1/*1 *6/*6 
  Concentration 
 (ng/mL)   
Day 14 
Observed 1752 ± 197 2462 ± 130 
Predicted 1597 ± 80 3921 ± 196 
     
Day 56 
Observed 1466 ± 134 4600 ± 262 
Predicted 1594 ± 80 4074 ± 204 
    
Day 84 
Observed 1329 ± 166 3991 ± 194 
Predicted 1284 ± 64 3989 ± 199 
    
Day 112 
Observed 1446 ± 283 3741 ± 225 
Predicted 1140 ± 57 4170 ± 209 
    
Day 140 
Observed 1420 ± 221 5404 ± 319 
Predicted 1595 ± 80 5698 ± 285 
    
Day 168 
Observed 1292 ± 278 5621 ± 284 
Predicted 1284 ± 64 5219 ± 261 
    
Day 224 
Observed 1353 ± 198 6861 ± 382 
Predicted 1595 ± 80 5698 ± 285 
Data represents mean ± SD. Simulations: n=100 with 38.5 % female and age-range of 20-40 
years. 
3.2 Step 2: Adult simulations with lumefantrine-efavirenz drug-drug interactions  
To further validate the proposed model, DDIs were simulated between lumefantrine and 
efavirenz using the Simcyp ‘Healthy Volunteer’ population group. The impact of the predicted 
DDI on lumefantrine pharmacokinetics was within the range of the observed data reported in 
the absence and presence of efavirenz (Huang et al., 2012) (Supplementary materials Figure 
S3), with Cmax, tmax and AUC predictions within 2-fold of those reported (Huang et al., 2012) 
(Table 3).  Furthermore, the predicted day 7 lumefantrine concentration (Cd7) in the presence 
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of efavirenz, 679 ± 361 ng/mL, was within 2-fold of that observed (544 ± 432 ng/mL) (Table 
3). 
 
Table 3: Summary of predicted and observed PK parameters of lumefantrine in the 
absence and presence of efavirenz in healthy adults. 
    Cmax AUClast tmax Cd7 
 
 (µg/mL) (µg/mL.h) (h) (ng/mL) 
- EFV 
Predicted 12.39 (8.12-19.2) 276 (320-711) 3.6 (2-5.9) 1162 ± 557  
Observed 11.6  (9.5-17.4) 418 (339-693) 2.0 (2-6) 1020 ± 478 
+ EFV 
Predicted 12.42 (7.14-18.7) 236 ± (201-617) 4.2 (0.4-5.7) 679 ± 361  
Observed 12.1 (10.6-16.4) 331 ± (270-503) 6.0 (0.5-6) 554 ± 432 
Data represents geometric mean ± 90 % CI or mean ± SD (for Cd7). Simulations: n=12 with 
16.6 % female and age-range of 24-53 years. EFV: efavirenz. 
 
The model was then extended to assess its application within an African population group.  A 
recent study reported lumefantrine Cd7 in a Tanzanian population group for *1/*1 and *6/*6 
population groups (Maganda et al., 2016b; Maganda et al., 2015).  In lieu of the development 
of a Tanzanian population group, a recently developed Simcyp ‘South-African’ population 
group was used as a surrogate for a Tanzanian population group to predict lumefantrine Cd7 in 
*1/*1 and *6/*6 population groups (Figure 2). In this simulation, we assumed some similarity 
between the population groups in terms of body weight demographics (Hayes et al., 2015). 
Predictions of median lumefantrine Cd7 in the absence of efavirenz, for both *1/*1 and *6/*6, 
were well predicted and within 2-fold of that reported (Maganda et al., 2016b) (Table 4).  In 
the presence of efavirenz, the *1/*1 and *6/*6 predicted median Cd7 were within 2-fold of that 
reported.  In the absence of efavirenz, CYP2B6 genotypes had no significant impact on any 
pharmacokinetic parameters. However, in the presence of efavirenz, the Cmax and Cd7 for the 
*6/*6 population were significantly reduced (P<0.01), 17500 to 9010  ng/mL and 901 to 201 
ng/mL, when compared to the *1/*1 population group (Table 4). 
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Table 4: Summary of the simulated lumefantrine pharmacokinetics parameters in the absence and presence of efavirenz in South African 
adults with CYP2B6*1/*1 and CYP2B6*6/*6 genotypes. 
Parameters Lumefantrine alone Lumefantrine plus Efavirenz 
 
*1/*1  
Median (Range) 
 
*6/*6  
Median (Range) 
 
*1/*1  
Median (Range) 
 
*6/*6  
Median (Range) 
 
Cmax (ng/mL) 17500 (8350-28500) 17500 (8350-28500) 12100 (5550-21500) 9010 (4200-16800) 
AUC0-inf (ng/mL.d) 60002 (20195-138896) 60002 (20195-138896) 38243 (12171-92638) 25578 (7685-67347) 
tmax (h) 22.59 (22.54-22.64) 22.59 (22.54-22.64) 22.59 (22.10-22.60) 22.59 (22.05-22.64) 
Predicted  Cd7 (ng/mL) 901 (13-4620) 901 (13-4620) 382 (1-1650) 201 (1-1280) 
Observed Cd7 (ng/mL) 1000 (686–1929) 893 (562–1732) 299 (253–384) 226 (173–278) 
 
Data represents median (range). Simulations: n=59 with 52.3 % female and age-range of 21-65 years.
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3.3 Step 3: Paediatric simulations with efavirenz  
Having established the ability of the proposed model to predict adult lumefantine-efavirenz  
DDIs in genotyped African population groups, the model was expanded to assess the impact 
of such interactions in paediatric population groups.  
Simulations were performed in a custom developed Ugandan paediatric population group (see 
supplementary materials) with validation of efavirenz pharmacokinetics based on WHO weight 
based dosing recommendation for children and compared to a report of efavirenz dosing in 
Ugandan paediatric malaria patients (Fillekes et al., 2011) where 41 children were dosed at 300 
mg once daily.   Based on this dosing approach, predicted efavirenz concentration profiles 
(Supplementary materials Figure S4) were within the range reported (Fillekes et al., 2011) with 
the predicted Cmax for the population group, 3.59 mg/L (1.65-9.52 mg/L), within 2-fold of that 
reported 3.62 mg/L (2.86-4.38 mg/L) (Table 5). 
 
Table 5: Summary of predicted and observed efavirenz pharmacokinetics parameters in 
HIV-infected Ugandan children. 
  Cmax 
(mg/L) 
AUC0-last 
(mg/L.h) 
tmax 
(h)  
Predicted 3.59 (1.65-9.52) 33.52 (11.24-94.43) 2.4 (2.3-2.6) 
Observed 3.62 (2.86-4.38) 54.52 (44.53-64.51) 4.0 (3.2-4.8) 
Data represents mean (range). Simulations: n=41 with 58.5 % female and age-range of 3-12 
years. 
 
To further validate the ability of the model to predict efavirenz plasma concentrations in 
paediatric population groups, predictions were stratified over weight ranges, where efavirenz 
was dosed based on body weight using the Ugandan population group, and compared with 
published population-based data (Luo et al., 2016)  for matching weight ranges (Figure 3).  In 
all weight groups, the predicted mean plasma concentration profiles were generally well 
predicted, and the 5th and 95th prediction percentiles spanned the range of observed population 
data points for each weight banding.   
Further, following a high dose of efavirenz (25mg/kg), dosed once daily to 2-3 year old 
Ugandan children, simulations of the mean efavirenz plasma concentration profile (Figure 4) 
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were in good agreement with data published (Pressiat et al., 2017), with prediction of C12h and 
AUC0-24 within 2-fold of that reported (Supplementary materials Table S3).   
To further validate the ability of the model to predict efavirenz concentrations in CYP2B6 
genotyped paediatric subjects, simulations were performed in a South African paediatric 
population group where efavirenz was dosed at 300 mg to 6-7 years old (Figure 5), and where 
genotyped plasma concentration had been previously published in a South African paediatric 
population group (Viljoen et al., 2012) for 2 hours around the C12h.  Model predictions for both 
*1/*1 and *6/*6 where generally in good agreement with that published, with a slight under 
prediction for *1/*1 subjects.    Further, *6/*6 demonstrated a significantly higher Cmax, 8.27 
ng/mL (3.18-17.44 ng/mL), when compared to *1/*1, 4.26 ng/mL (1.45-7.98 ng/mL) (P < 
0.001) (Supplementary materials Table S4). 
 
3.4 Step 4: Paediatric simulations with lumefantrine-efavirenz drug-drug 
interactions 
Having demonstrated the ability to predict efavirenz concentrations in paediatric subjects, we 
next attempted to predict lumefantrine-efavirenz based DDIs in African population groups.  We 
utilised the Ugandan paediatric population group and reported pharmacokinetics in a Ugandan 
population group (Parikh et al., 2016), to predict lumefantrine concentrations in the presence 
and absence of efavirenz (Figure 6). This clinical study used for validation (Parikh et al., 2016) 
applied weight-based dosing across a wide age range (3.1-8.6 years) with dosing that spanned 
different weight bands, but did not present plasma concentration profiles genotyped for 
CYP2B6.  Results presented in Figure 6 are therefore stratified for two extreme cases of an 
entire population of CYP2B6 *1/*1 or entirely CYP2B6 *6/*6, and this represent the ‘best’ 
and ‘worst’ clinical scenarios. 
When considering the two extreme scenarios, model predictions of the final dose Cmax were 
within 2-fold of that reported (Parikh et al., 2016), and spanned a range of total values (2060-
11083 ng/mL) that were similar to the population range reported (2611-6673 ng/mL) (Table 
6).   In the absence of efavirenz, the predicted *1/*1 and *6/*6 lumefantrine profiles are largely 
overlapping with no significant differences in the last Cmax between genotypes (Table 6).  
Further, model prediction of Cd7, (Figure 6), were within 2-fold of that reported (Parikh et al., 
2016) (Table 6) in the absence of efavirenz. 
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In the presence of efavirenz, the median last-dose Cmax was significantly lower (P < 0.01) in 
the *6/*6 group (for both weight bands) (5-15 kg: 1532 ng/mL; 15-25kg: 1979 ng/ml) 
compared to the *1/*1 group (5-15 kg: 2494 ng/mL; 15-25kg: 2994 ng/ml) (Table 6). Similarly 
Cd7 was significantly lower (P < 0.01) in the *6/*6 group (5-15 kg: 20 ng/mL; 15-25kg: 51 
ng/ml) compared to the *1/*1 group (5-15 kg: 120 ng/mL; 15-25kg: 221 ng/ml) (Table 6). 
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Table 6: Summary of simulated lumefantrine pharmacokinetic parameters in the absence and presence of efavirenz in children with 
CYP2B6 *1/*1 and CYP2B6 *6/*6 genotypes. 
 
      Weight Band Cmax (ng/mL) AUC0-inf  (ng/mL.d) tmax (h) Cd7 (ng/mL) 
L
u
m
ef
a
n
tr
in
e 
CYP2B6 *1/*1  Predicted 
5-15 kg  3649 (2093-5857) 15669 (6194-40144) 22.5 (14.1-30.9) 555 (58-2027) 
15-25 kg 5007 (2060-10055) 19855 (5906-60356) 22.5 (14.1-30.9) 675 (27-3115) 
CYP2B6 *6/*6  Predicted 
5-15 kg  3649 (2093-5857) 15669 (6194-40144) 22.5 (14.1-30.9) 555 (58-2027) 
15-25 kg 5215 (2151-11083) 21083 (6056-64479) 22.5 (14.1-30.9) 672 (22-3105) 
Non-genotyped Observed - 4642 (2611-6673) 10547 (5822-15271) 23.3 (19.2-27.1) 340 (199-481) 
L
u
m
ef
a
n
tr
in
e 
+
 
E
fa
v
ir
en
z
 CYP2B6 *1/*1  Predicted 
5-15 kg  2494 (702-5193) 7617 (1299-18962) 22.5 (14.1-30.9) 120 (1-508) 
15-25 kg 2994 (893-5933) 10005 (1949-25938) 22.5 (14.1-30.9) 221 (1-1049) 
CYP2B6 *6/*6  Predicted 
5-15 kg  1532 (383-3420) 3691 (596-9807) 22 (14-30) 20 (1-81) 
15-25 kg 1979 (505-4582) 5146 (912-13743) 22.5 (14.1-30.3) 51 (1-269) 
Non-genotyped Observed - 3795 (2543-5047) 6053 (3840-8267) 23.3 (19.2-27.1) 111 (65-157) 
Data represents median (range). Simulations: n=31 with 50 % female and age-range of 3.1-8.6 years. 
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3.5 Step 5: Paediatric dose evaluation prediction 
Given the variability in CYP2B6 polymorphisms across different population groups, it was 
essential to assess the risks associated with antiretroviral agents, such as efavirenz, attenuating 
CYP-mediated drug metabolism of antimalarials, where variability in efavirenz plasma 
concentrations, as a result of poor metabolism, may alter antimalarial concentrations in a highly 
polymorphic CYP2B6 population groups.  Confounding this is CYP2B6 ontogeny, where 
expression is known to be low at < 1 years (10-30% of adult mRNA/protein/activity) and 
stabilising at approximately 18 years of age (Croom et al., 2009; Pearce et al., 2015).  
Simulations were therefore conducted to predict the impact of efavirenz on lumefantrine 
plasma concentrations for subjects aged 0.25-13 years of age where weight-based dosing was 
used, with efavirenz dosed for at least 20 days prior to the initiation of lumefantrine to establish 
the stable induction of CYP3A4. 
In the absence of an increase in the treatment duration, significant difference in the percentage 
of subjects possessing a Cd7 above the 280 ng/mL threshold were apparent (P < 0.001) between 
*1/*1 and *6/*6 alleles for all dosing bands, with 1-11% of *6/*6 subjects attaining this 
threshold (see supplementary materials Table S5). With an increase in treatment duration of 5- 
or 7-days (Figure 7), an increase in the percentage of subjects attaining the target Cd7 was 
evident  (see supplementary materials Table S5) and most noticeable for the *6/*6 population 
group for the 7-day regimen where 28-57% of subjects attained the target concentrations across 
all dosing bands (Table 7). 
Further, extension of the dosing interval from 5-days to 7-days did not alter the half-life within 
the same genotyped subjects (*1/*1 or *6/*6). However a significant decrease in the half-life 
(P < 0.001) was noted when comparing the same dosing regimen extension but across the 
different genotypes.  Additionally, when comparing the half-life across increasing dosing-
bands, the half-life increased but this was not significant (P > 0.05) (Table 7).  
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Table 7: Summary of predicted mean day 7 lumefantrine concentrations during a 5 and 7-day treatment schedule in children stratified 
for CYP2B6*1/*1 and CYP2B6*6/*6 genotypes (n=100). 
 
Dosing Mean Cd7 (Range) (ng/mL)  Mean half-life (t1/2) (SD) (h) 
Age-
band 
(years) 
Weight-
band 
(kg) 
Lumefantrine 
(mg) 
Efavirenz 
(mg) 
CYP2B6*1/*1 CYP2B6*6/*6  CYP2B6*1/*1 CYP2B6*6/*6  
     5-day 7-day 5-day 7-day 5-day 7-day 5-day 7-day 
0.25 - 1 5 - 6.9 120 300 
1100 2800 306 1030 27.18 27.18 19.12 19.12 
(1-5585) (45-10345) (1-1497) (11-4308) (8.36) (8.36) (6.98) (6.98) 
1 - 4 7 - 13.9 120 400 
325 1013 65 305 28.12 28.12 21.03 21.03 
(1-1515) (17-3327) (1-259) (3-1072) (10.68) (10.68) (7.91) (7.91) 
4 - 8 14 - 16.9 240 500 
496 1456 100 438 29.12 29.12 22.11 22.11 
(1-1735) (45-4374) (1-380) (7-1568) (11.11) (11.11) (8.51) (8.51) 
8 - 13 17 - 24.9 240 600 
397 1053 100 359 30.62 30.62 24.93 24.93 
(3-1843) (56-3456) (1-390) (9-1315) (12.28) (12.28) (9.78) (9.78) 
 
Half-life was calculated from the final dose. SD: standard deviation. 
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4. DISCUSSION 
In 2013 it was estimated that 35 million people were living with HIV worldwide with sub-
Saharan Africa accounting for 71% of the total global burden, predominantly centred around 
Southern and Eastern African countries (South Africa > Nigeria > Mozambique > Uganda > 
Tanzania > Zambia > Zimbabwe > Kenya > Malawi > Ethiopia) ((UNAIDS). 2014).  Further 
at least 1 million pregnancies are complicated by the co-infection of malaria and HIV, resulting 
in a paediatric population group which may be subjected to complex pharmacotherapy 
(Gonzalez et al., 2012). 
Although HIV infection can directly impact upon malaria through changes in parasitaemia 
(Omoti et al., 2013), as well as the severity of the disease and mortality rates during pregnancy 
(Desai et al., 2007), the use of weight-based dosing strategies and fixed-dosed combination 
system for both antiretroviral therapies and antimalarial therapies can hinder mitigation of 
DDIs.   
A recent systematic review (Seden et al., 2017), assessed the literature reported DDIs between 
subjects co-administered with HIV and malaria pharmacotherapy.  They identified efavirenz 
as being an important mediator of DDIs, particularly when co-administered with artemisinins 
(and lumefantrine), leading to reduced antimalarial plasma concentrations and potential 
recrudescence. 
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI), being predominantly 
metabolised by CYP2B6 and an inducer of CYP3A4.  These interactions with CYP isozymes 
can complicate both antiretroviral therapy and antimalarial therapy.  Further confounding this, 
is the fact that CYP2B6 is highly polymorphic, with the most common variant alleles resulting 
in two amino acid changes, Q172H and K262R, and referred to as the *6/*6 polymorphism 
with wild-types as *1/*1.  The *6/*6 polymorphism has been reported to lead to a 65 % 
reduction in protein expression and 50 % reduction in mean enzyme activity in the homozygous 
state (Lang et al., 2001).  Further, although CYP2B6 contributes  towards between 2-10 % of 
total CYP content (Wang and Tompkins, 2008), the *6/*6 genotype can result in a 2- or 3-fold 
higher efavirenz plasma concentrations (Haas et al., 2004; Rodriguez-Novoa et al., 2005; 
Rotger et al., 2005; Tsuchiya et al., 2004), with this genotype being more frequent in African 
population groups than Caucasian population groups (King and Aberg, 2008; Klein et al., 
2005).  A consequence of this alteration in efavirenz plasma concentration would be a greater 
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ability of efavirenz to induce CYP3A4 (Habtewold et al., 2013; Hariparsad et al., 2004; Mouly 
et al., 2002). 
Pharmacokinetics assessment of drug therapy in paediatric population groups is often neglected 
due to ethical complications and the sparse plasma sample collections inherent in such 
population groups.  However, PBPK represents a novel modelling strategy that has gained 
regulatory acceptance (Wagner et al., 2015) in its applications in the paediatric population and 
has been used previously to model malaria pharmacokinetic in special population groups such 
as paediatrics (Olafuyi et al., 2017b) and pregnancy populations (Olafuyi et al., 2017a). 
Recently, we demonstrated the ability of rifampicin to alter antimalarial concentrations through 
a CYP3A4-induction process, and thereby reducing Cd7 (Olafuyi et al., 2017b).  In this present 
study, we addressed the impact of a similar induction process with the confounding complexity 
of potential CYP2B6 polymorphisms on the pharmacokinetics of lumefantrine in paediatric 
population groups.  In this manuscript, we adopted a 5-stage modelling approach which 
spanned efavirenz and efavirenz-lumefantrine DDI model predictions in adults in African and 
Healthy Volunteer population groups (Steps 1 and 2), followed by efavirenz and efavirenz-
lumefantrine DDI model predictions in African and Healthy Volunteers paediatric populations 
(Steps 3 and 4).  This culminated in predictions of potential DDI risks in CYP2B6 genotyped 
paediatric population groups with an assessment of the impact of a revised dosing adjustments 
on Cd7 (Step 5). 
Although efavirenz is a compound that has been previously developed and validated by 
researchers associated with Simcyp (Ke et al., 2016),  Step 1 attempted to predict efavirenz 
concentration profiles in a African population groups with altered CYP2B6 abundances (6.9 
and 2.4 pmol/mg for *1/*1 and *6/*6 genotypes), in contrast to those of the default values set 
by Simcyp within the Healthy Volunteer population group (17 pmol/mg and 6 pmol/mg). This 
step integrated revised CYP2B6 abundances for EM and PM phenotypes, based on the 
incorporation of these abundances into a Simcyp developed South African population group, 
and in-lieu of any further published Ugandan CYP2B6 abundances (Critical Path to TB Drug 
Regimens, 2016; Gardner, 2016). 
In adults, successful predictions of efavirenz concentrations were validated against 2 clinical 
in both single (Table 1) and multiple dosing (Table 2) regimens in Ugandan population groups, 
with model predictions within 2-fold of the reported Cmax, AUC or single day point 
concentrations from clinical studies for each genotype.  Following validation of genotype-
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specific efavirenz pharmacokinetics, we next attempted to simulate the proposed lumefantrine-
efavirenz DDI, whereby efavirenz would induce CYP3A4 expression, resulting in reduce 
lumefantrine plasma concentrations. 
A Healthy Volunteer population was first utilised to demonstrate successful Cd7 predictions, 
which were within 2-fold of that reported (Huang et al., 2012).  This was subsequently extended 
to simulate the DDI in a South-African population group, as a surrogate for the use of a 
Tanzanian population group, where the clinical DDI was reported within each CYP2B6 
genotype (Maganda et al., 2016b; Maganda et al., 2015).  Based on recent age-weight 
relationships for malaria subjects in Africa, we assumed that the South African population 
group would demonstrate similar demographics to that of the Tanzanian population (Hayes et 
al., 2015), and this was further supported by the lack of reported CYP2B6 specific abundance 
data for EM or PM phenotypes within the Tanzanian population group. 
As expected, in the absence of efavirenz, Cd7 were well predicted for both genotypes (Table 4), 
confirming that in the absence of efavirenz, CYP2B6 *6/*6 has no significant effect on 
lumefantrine pharmacokinetics (Maganda et al., 2016b).  In the presence of efavirenz, 
simulations with the *1/*1 and *6/*6 population groups resulted in predictions for median Cd7 
to within 2-fold of those reported, albeit with a broader range of values across the simulation 
study (Maganda et al., 2016b; Maganda et al., 2015), and demonstrated that lumefantrine 
pharmacokinetics are significantly altered following co-treatment with efavirenz. 
Having established a working model for genotype-based DDI predictions in adults, we 
subsequently assessed the ability to predict efavirenz plasma concentrations within an African 
paediatric population group, using a custom developed Ugandan paediatric population group 
and validated against 3 clinical studies employing/reporting weight-based dosing strategies in 
non-genotyped (Fillekes et al., 2011; Luo et al., 2016; Pressiat et al., 2017) and genotyped 
subjects (Viljoen et al., 2012).  The validation of efavirenz concentrations within and African 
paediatric population group was important as any changes in efavirenz plasma concentrations, 
for example as a result of the impact of CYP2B6 genotypes, would be the key function for 
driving a DDI with lumefantrine, the extent of which would, therefore, be sensitive to change 
in the available of efavirenz.  For both non-genotyped (Supplementary materials Figure S4, 
Figure 3-4) and genotype predictions (Figure 5), overall 5th and 95th percentiles of the 
mean/median predicted profiles were within the range reported in existing published literature 
and contributed to our efavirenz validation attempts. However, for the high dose administration 
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(25 mg/kg) (Figure 4), we were unable to capture the wide variability in the absorption phase 
reported (Pressiat et al., 2017) and this may have been a result of the influence of food on the 
absorption and bioavailability of efavirenz. 
Having established a working model for efavirenz-mediated DDIs in paediatric predictions, we 
addressed the ability of this model to predict the lumefantrine-efavirenz DDI, and validation 
was attempted based upon a report of the interaction in Ugandan children across an age range 
of 3.1-8.6 years and weight range of 11.4-25.1 kg, using weight-based dosing for both efavirenz 
and lumefantrine (Parikh et al., 2016) (Figure 6).   The reported study did not differentiate 
lumefantrine plasma concentration profiles by genotype, although our simulations were 
stratified for two extreme cases of an entire population of CYP2B6 *1/*1 or entirely CYP2B6 
*6/*6, and this represent the ‘best’ and ‘worst’ clinical scenarios.  Further, the wider Cd7 range 
simulated in our studies for purely *1/*1 populations was outside of the range reported (Parikh 
et al., 2016), however we considered the ‘best’ and ‘worst’ clinical scenarios and a proportional 
‘mixed’ genotype population (as potentially sampled by the reported study (Parikh et al., 2016)) 
would have corrected this disparity. 
This study demonstrated a significant difference in median Cd7 in the presence and absence of 
efavirenz and confirmed the capability of efavirenz to initiate this DDI.  In our model 
simulations across all weight bands, we demonstrated a similar significant reduction in Cd7, 
which was more apparent and resulted in significantly lower (P <0.001) lumefantrine in Cd7 in 
the *6/*6 compared to *1/*1 population group (Table 6). 
We previously demonstrated that an increase in lumefantrine treatment duration would 
significantly increase Cd7 under rifampicin-mediated CYP3A4 induction, and this formed the 
basis of attempting to address the significantly lower number of *6/*6 subjects capable of 
attaining target Cd7 (Olafuyi et al., 2017b). Orally administrated lumefantrine is known to 
display saturated absorption kinetics (Ashley et al., 2007), and therefore increasing the dose of 
lumefantrine administrated within each fixed-dose combination would not be appropriate.  
Therefore, having established the risk of DDI between efavirenz and lumefantrine (Step 4) the 
treatment duration was extended to a 5-day or 7-day regimen.   
The change in dosing schedule to 7-day regime resulted in a greater number of *6/*6 subjects 
attaining the target Cd7, with 28-57% of subjects (Table 7) attaining this across the age bands 
studied (Figure 7).  The greatest increase in those attained target Cd7 was evident with 1-4 years 
old (3-day: 1%; 7-day: 28%) (Table 7), and this may be accounted for by the maturation of 
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CYP3A4 which would be the key driver for influencing lumefantrine plasma concentrations.  
CYP3A4 ontogeny is known to rapidly increase over this age range (Salem et al., 2014) to 
approach adult levels at approximately 6-years onwards.   
Determination of the half-life of lumefantrine, typically difficult in paediatrics subjects, given 
the long-terminal half-life (2-6 days) (Djimde and Lefevre, 2009) and the often sparse nature 
of plasma collections.  A recent study by Parikh et al (2016) in Ugandan children (3.1-8.6 
years) reported the median half-life of lumefantrine, when dosing in the presence of efavirenz, 
as 23.7 hours.  When comparing model predictions of the half-life across all age range 
simulations (0.25-13 years), our predictions are broadly in line with those of Parikh et al (2016).  
Further, the extension of the dosing interaction from 5-days to 7-days does not alter the half-
life within the same genotype (Table 7), suggesting this extension would not alter the 
elimination clearance of lumefantrine.  As expected, the *6/*6 subjects demonstrated a 
significant decrease in half-life, which would correspond to the increased circulating 
concentration of efavirenz, thereby handing the DDI and reducing the residency of 
lumefantrine within the subjects (Table 7).  However, although CYP2B6 ontogeny may 
influence circulating efavirenz (Croom et al., 2009; Pearce et al., 2015), the impact of this DDI 
may be less apparent or masked by the rapid changes in CYP3A4 ontogeny across this range, 
which would directly influence circulating lumefantrine concentrations.  Further clinical 
studies are encouraged` to delineate the relative impact of CYP3A4 and CYP2B6 ontogeny on 
extent of this DDI. 
Given the resource limitations and cost implications of dose extensions, the authors halted the 
study at a 7 day dosing regimen and believe further, extended dosing would likely not succeed 
clinically, due to medicine adherence concerns in resource limited countries (Yeung et al, 
2005). Whilst a 5- or 7-day extension may not result in all subjects attaining the target Cd7, the 
proposed extension can be considered to be a pragmatic approach, given the complexity of 
treatment regimens in developing countries.  Further, using a standard 3-day regimen Parikh et 
al (2016) demonstrated that the median lumefantrine Cd7 for 3.1-8.6 year old, 111 ng/mL, was 
significantly below the target concentration in the presence of efavirenz.  Therefore, although 
there may be some scope for further optimisation, the 5- or 7-day regimen would provide a 
greater level of subject’s attainment appropriate Cd7 compared to existing 3-day regimens.  
Despite the paucity in clinical data investigating altered dosing regimens for efavirenz-
mediated DDI with lumefantrine, the relationship between the DDI, resultant reduction in 
lumefantrine concentration (primarily based around changes in day-7 concentration) and the 
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emergence of recurrent malaria has recently been highlighted in studies by Parikh et al (2016) 
and Maganda et al (2014). Finally, a number of groups are now advocating increasing the 
dosing duration to counteract this interaction (Hoglung et al, 2015) (Maganda et al, 2015). 
5. CONCLUSION 
Although the rates of malaria infections have decreased globally, persistent complications still 
exist in ‘at-risk’ population groups, particularly paediatrics and pregnant women (World Health 
Organisation, 2015, 2016b).  This is further confounded in situations where genetic 
polymorphisms contribute towards cross-population variability in complex pharmacokinetics 
situation, such as antiretroviral mediated-DDIs, may increase the risk of parasite resistance and 
treatment recrudescence.   
Exploration of these risks is difficult clinically, however population-based pharmacokinetic 
modelling provides a practical approach for simulating such complex interactions.  This study 
focussed on predicting the risk of efavirenz-mediated DDIs on lumefantrine pharmacokinetics 
in African paediatric population groups with consideration of the polymorphic nature of 
CYP2B6.  We demonstrated that an extension of the current artemether-lumefantrine treatment 
regimen from 3-days to 7-days would counteract the reduction in efavirenz metabolism 
common with the *6/*6 genotype and hence enhance the attainment of the target day-7 
lumefantrine concertation in both *1/*1 and *6/*6 genotype groups, thereby reduce the risk of 
recrudescence.  
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List Of Figures 
Figure 1:  Model development strategy 
 
Figure 2: Simulated drug-drug interaction between lumefantrine and efavirenz in a 
South African population groups.  
Lumefantrine was dosed for 6 doses of 480 mg, twice daily for three days commencing on day 
20, in the absence (A) and presence (B) of efavirenz (600mg once daily) dosed for the entire 
study duration to 59 South African healthy adults.  *1/*1 (EM) and *6/*6 (PM) genotype 
pharmacokinetic profiles are indicated by the black and red colour respectively. Median 
observed plasma day-7 lumefantrine concentrations (Maganda et al., 2016b) are represented 
by the black open circle (EM) and red closed square (PM) with error bars indicating standard 
deviations.  Solid lines represent predicted median plasma concentration with dashed lines 
indicated 5th and 95th percentiles.   
 
Figure 3: Simulated plasma concentration-time profile of body weight efavirenz dosing 
in Healthy Volunteers 
A 10x10 trial was run with efavirenz dosed in a standard body-weight based single daily dose 
regimen for 30 days.  Results are presented stratified based on body-weight bandings each 
possessing at least 80 virtual trial subjects.  Solid lines represent mean predictions with dotted-
lines representing 5th-95th percentile range for the final dose.  Open circles represent data for 
observed study for each body weight banding (Luo et al., 2016).  
 
Figure 4: Simulated plasma concentration-time profile of efavirenz dosed at 25 mg/kg to 
2-3 years old Ugandan children   
A dose of 25 mg/kg efavirenz was administered once daily to 2-3 years old Ugandan children 
(n=53) using the Ugandan Simcyp population group.  Solid lines represent mean predictions 
with dotted-lines representing 5th-95th percentile range.  Open circles represent data for 
observed study (Pressiat et al., 2017) originating from Burkina Faso and Cote d’Ivoire. 
 
Figure 5: Simulated plasma concentration-time profile of efavirenz in South African 
children stratified by genotype 
A dose of 300 mg was administered to 60 children (using the South African population group), 
aged between 6-7 years and possessing a weight of 20-24.9kg, for 25 days. Simulations were 
run for genotypes of all subjects being either *1/*1 or all *6/*6 genotypes.  Results are 
presented for day 20 with solid lines representing median predictions with dotted-lines 
representing 5th-95th percentile range.  Open circles represent data for observed study (Viljoen 
et al., 2012) from a South African population group. 
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Figure 6: Simulated median plasma concentration-time profile of lumefantrine 
administered to Ugandan children in the absence and presence of efavirenz. 
Lumefantrine (LUM) and efavirenz (EFV) were dosed to Ugandan children aged 3-9 years of 
age using weight-based dosing strategies of (A) 5-15 kg (LUM: 120 mg per dose; EFV: 200 
mg per dose) and (B) 15-25 kg (LUM: 240 mg per dose; EFV: 250-300 mg per dose) with 
simulated profiles for population groups of all CYP2B6 *1/*1 or all CYP2B6 *6/*6.  All 
simulations included 40-50 subjects per dosing band.  Open circles and error bars represent 
mean and standard deviation respectively (Parikh et al., 2016).  Dotted-lines are represent the 
5th-95th percentile range. Dashed horizontal and vertical lines originated from each axis 
represent day 7 concentration (280 ng/mL) and simulation day. 
 
Figure 7: Simulated mean plasma concentration-time profile of lumefantrine 
administered in a 5-day or 7-day regimen to Ugandan children  
Lumefantrine (LUM) and efavirenz (EFV) were dosed to Ugandan children aged 0.25-13 years 
of age using weight-based dosing strategies (0.25-1 year-old (120mg LUM/300mg EFV), 1-4 
year-old (120mg LUM/400mg EFV), 4-8 year-old (240mg LUM/500mg EFV) and 8-13 year-
old (240mg LUM/600mg EFV)), with population groups simulating all EFV extensive 
metabolisers (CYP2B6 *1/*1) or poor metabolisers (CYP2B6 *6/*6).  All simulations included 
40-50 subjects per dosing band.  Solid lines represent mean plasma concentrations. 
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